Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Application of New Data in B-Cell Malignancies From ASCO and EHA 2020: Waldenström Macroglobulinemia, Mantle Cell Lymphoma, Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma

ASCO 2020 Virtual Meeting/May 29-31, 2020
EHA 2020 Virtual Meeting/June 11-21, 2020
Listen to Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss the implications of recent trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).
John Allan, MD
Jennifer R. Brown, MD, PhD
Released: August 31, 2020

In this episode, Jennifer R. Brown, MD, PhD, and John Allan, MD, discuss recent key clinical trial results in Waldenström macroglobulinemia, mantle cell lymphoma, Hodgkin lymphoma, and DLBCL presented at the 2020 annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA). Studies include:

  • ASPEN: Zanubrutinib vs ibrutinib in WM
  • OASIS: Ibrutinib, venetoclax, and obinutuzumab in MCL
  • GHSG HD17: PET-guided therapy in HL
  • KEYNOTE-024: Pembrolizumab vs brentuximab in HL
  • ALEXANDER: AUTO3 in DLBCL

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program: https://www.clinicaloptions.com/oncology/conference-coverage/global-asco-eha-2020

Acknowledgements

Supported by an educational grant from
AstraZeneca

Related Content

Amer M. Zeidan, MBBS, discusses novel and investigational therapies for treating patients with myelodysplastic syndromes (MDS) in this commentary from Clinical Care Options (CCO)

Amer Zeidan, MBBS Released: November 22, 2021

Downloadable PDF with expert answers to clinicians’ questions on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Released: November 18, 2021

In this commentary from Clinical Care Options (CCO), Dr. Jennifer Woyach discusses patient education and shared decision making in CLL

Jennifer Woyach, MD Released: November 17, 2021

Gain key clinical insights with this slideset from Clinical Care Options (CCO) on how ADCs use for cancer therapy can cause ocular toxicity

Asim V. Farooq, MD Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue